Healthcare entity

COVID-19 Vaccine

Product

Of the tracked stories, 1 of 2 also mention ACOG, the most common co-covered peer. The 119-day window averages about 0.1 stories each week. Each story carries 8 original sources on average, compared with 5.7 for the broader beat in this window.

Last mentioned: Jul 21, 2026

RSS updates
Share

Entity pulse

Recent coverage · COVID-19 Vaccine

↑
2 stories
6.5 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about COVID-19 Vaccine

Of the tracked stories, 1 of 2 also mention ACOG, the most common co-covered peer. The 119-day window averages about 0.1 stories each week. Each story carries 8 original sources on average, compared with 5.7 for the broader beat in this window. The average consequence score is 6.5, matching the 6.5 beat baseline for this window. The clearest coverage concentration is health-it: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Healthcare stories mentioning COVID-19 Vaccine across the period from March 25, 2026 to July 21, 2026.

Stories tracked
2
Per week
0.1
Sources per story
8

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 230 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering COVID-19 Vaccine. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Cramer Endorsement & 109% YTD Gain

    Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.

  2. Quarterly Update

    Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.

  3. Post-Pandemic Decline

    Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.

  4. COVID Vaccine Success

    Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

Stories mentioning COVID-19 Vaccine 2

Health IT Positive

Large Study Confirms Maternal COVID-19 Vaccination Protects Infants Post-Birth

A comprehensive multi-site study has confirmed that COVID-19 vaccination during pregnancy significantly reduces the risk of hospitalization for infants in their first six months of life. The findings provide robust evidence for the benefits of transplacental antibody transfer in protecting neonates who are not yet eligible for vaccination.

14 sources

Source: publicradiotulsa.org · wcsufm.org

COVID-19 Vaccine is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.